NCT00620100View on ClinicalTrials.gov

To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions
Breast Neoplasms
Interventions
DRUG

Docetaxel

Trial Locations (2)

Unknown

Sanofi-Aventis, Vienna

Sanofi-aventis, Warsaw

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00620100 - To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent | Biotech Hunter | Biotech Hunter